October 09, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in the field of migraine.

Additional eligibility requirements are listed below.

More Information

Application requirements
AbbVie is looking for early-stage biotech companies that fit the following criteria:

Have primary business location in US, France or Germany

Be an early stage-startup focused on developing novel therapeutic approaches for migraine that could include both central and peripheral mechanisms for treating acute migraine and migraine prevention.

Related research areas in pain with potential application(s) to migraine will also be considered.

Excluded are devices, neuromodulation technologies and similar technologies.

For additional requirements refer to the Terms and Conditions document.

Therapeutic focus of this call for applications: Migraine

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

Application requirements AbbVie is looking for early-stage biotech companies that fit the following criteria:

Therapeutic focus of this call for applications: Migraine

Our latest News

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

New AI System Provides Treatment Recommendations for Complex Blood Cancers

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!

Application requirements
AbbVie is looking for early-stage biotech companies that fit the following criteria: